Head-to-head evidence
Bortezomib vs Ixazomib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Bortezomib
Marketed by Takeda Pharmaceutical Company
NCT00048230 · Phase 3 · completed
Although the record states that participants were randomized, it also describes a single-group, unmasked study and does not document the high-dose dexamethasone comparator in the listed arms. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT06140966 (registry estimate)
Ixazomib
Marketed by Takeda Pharmaceutical Company and partners
NCT01564537 · Phase 3 · completed
Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).
Next expected readout: March 2027 · NCT04068597 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · Ixazomib's landscape